Literature DB >> 1346169

Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

P LaRussa1, O Lungu, I Hardy, A Gershon, S P Steinberg, S Silverstein.   

Abstract

The nucleotide changes that result in two restriction endonuclease polymorphisms that differentiate wild-type varicella-zoster virus (VZV) from the vaccine strain were determined. Oligonucleotide primers that flank these sites were used to amplify the intervening sequences with the polymerase chain reaction to identify VZV DNA in clinical isolates. Restriction enzyme digestion of the amplification products distinguished vaccine and wild-type genomes from one another. This study confirms the feasibility of amplifying VZV sequences so that they may be detected in clinical specimens and provides a molecular epidemiological approach to strain identification of VZV in vesicular lesions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346169      PMCID: PMC240804     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Recombination in tissue culture between varicella-zoster virus strains.

Authors:  D E Dohner; S G Adams; L D Gelb
Journal:  J Med Virol       Date:  1988-03       Impact factor: 2.327

2.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

3.  Molecular epidemiology of live, attenuated varicella virus vaccine in children with leukemia and in normal adults.

Authors:  L D Gelb; D E Dohner; A A Gershon; S P Steinberg; J L Waner; M Takahashi; P H Dennehy; A E Brown
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

4.  The complete DNA sequence of varicella-zoster virus.

Authors:  A J Davison; J E Scott
Journal:  J Gen Virol       Date:  1986-09       Impact factor: 3.891

5.  Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia.

Authors:  R Mahalingam; M Wellish; W Wolf; A N Dueland; R Cohrs; A Vafai; D Gilden
Journal:  N Engl J Med       Date:  1990-09-06       Impact factor: 91.245

6.  Live attenuated varicella virus vaccine. Efficacy trial in healthy children.

Authors:  R E Weibel; B J Neff; B J Kuter; H A Guess; C A Rothenberger; A J Fitzgerald; K A Connor; A A McLean; M R Hilleman; E B Buynak
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

7.  Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella.

Authors:  C M Koropchak; G Graham; J Palmer; M Winsberg; S F Ting; M Wallace; C G Prober; A M Arvin
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Rapid diagnosis of varicella-zoster virus infections by countercurrent immunoelectrophoresis.

Authors:  H M Frey; S P Steinberg; A A Gershon
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

10.  The etiologic agents of varicella and herpes zoster; serologic studies with the viruses as propagated in vitro.

Authors:  T H WELLER; H M WITTON
Journal:  J Exp Med       Date:  1958-12-01       Impact factor: 14.307

View more
  59 in total

1.  Phylogenetic analysis of varicella-zoster virus: evidence of intercontinental spread of genotypes and recombination.

Authors:  Winsome Barrett Muir; Richard Nichols; Judith Breuer
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus.

Authors:  Yasuyuki Gomi; Hiroki Sunamachi; Yasuko Mori; Kazuhiro Nagaike; Michiaki Takahashi; Koichi Yamanishi
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Monitoring prevalence of varicella-zoster virus clades in Germany.

Authors:  A Sauerbrei; J Stefanski; A Philipps; A Krumbholz; R Zell; P Wutzler
Journal:  Med Microbiol Immunol       Date:  2010-10-31       Impact factor: 3.402

4.  A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades.

Authors:  Geoffrey A Peters; Shaun D Tyler; Charles Grose; Alberto Severini; Michael J Gray; Chris Upton; Graham A Tipples
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Reactivated and latent varicella-zoster virus in human dorsal root ganglia.

Authors:  O Lungu; P W Annunziato; A Gershon; S M Staugaitis; D Josefson; P LaRussa; S J Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 6.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping.

Authors:  Vladimir N Loparev; Antonio Gonzalez; Marlene Deleon-Carnes; Graham Tipples; Helmut Fickenscher; Einar G Torfason; D Scott Schmid
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Detection and genotyping of varicella-zoster virus by TaqMan allelic discrimination real-time PCR.

Authors:  Paul A Campsall; Nicholas H C Au; Julie S Prendiville; David P Speert; Rusung Tan; Eva E Thomas
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 9.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

10.  Reactogenicity to a live attenuated varicella vaccine in Canadian children.

Authors:  F Diaz-Mitoma; S A Halperin; D Scheifele
Journal:  Can J Infect Dis       Date:  2000-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.